Data standards for model-informed drug development: an ISoP initiative

This is a preview of subscription content, log in to check access.


  1. 1.

    Grasela T, Fiedler-Kelly J, Hitchcock D (2009) Improving the efficiency and ensuring the quality of data assembly for pharmacometric analysis. PAGE 18 Abstr 1552.

  2. 2.

    European Medicines Agency policy on publication of clinical data for medicinal products for human use.

  3. 3.

    Wilkins JJ, Jonsson EN (2013) Reproducible pharmacometrics [tutorial]. PAGE 22 Abstr 2774.

  4. 4.

    Marshall SF et al (2016) Good practices in model-informed drug discovery and development: practice, application, and documentation. CPT Pharmacomet Syst Pharmacol 5(3):93–122

    CAS  Article  Google Scholar 

  5. 5.

    Harnisch L, Matthews I, Chard J, Karlsson MO (2013) Drug and disease model resources: a consortium to create standards and tools to enhance model-based drug development. CPT Pharmacomet Syst Pharmacol 2:e34

    CAS  Article  Google Scholar 

  6. 6.

    Woosley RL, Myers RT, Goodsaid F (2010) The critical path institute’s approach to precompetitive sharing and advancing regulatory science. Clin Pharmacol Ther 87(5):530–533

    CAS  Article  PubMed  Google Scholar 

  7. 7.

    Romero K et al (2010) Pharmacometrics as a discipline is entering the “industrialization” phase: standards, automation, knowledge sharing, and training are critical for future success. J Clin Pharmacol 50(9 Suppl):9S–19S

    Article  PubMed  Google Scholar 

  8. 8.

    Karlsson MO, Conrado D, Romero K, Sarr C, Wilkins JJ (2017) Open innovation: towards sharing of data, models and workflows. Eur J Pharm Sci 109S:S65–S71

    PubMed  Google Scholar 

  9. 9.

    Radivojevic A, Schmidt H (2015) Datasets for pharmacometric analyses: internal review and standardization efforts. J Pharmacokinet Pharmacodyn 42:S81–S82

    Google Scholar 

  10. 10.

    Thanneer N, Roy A (2014) Best practices for preparation of pharmacometric analysis data sets. ACoP5.

Download references


The authors thank and acknowledge the contributions of ISoP Data Standards initiative group members: Ted Grasela, Jeffry Florian, Timothy Bergsma, Warwick Benger, Christian Rasmussen, Henning Schmidt, Liping Zhang, Scott Pivirotto, Stuart Pearce, Pragathi Kotha Venkata, Vishak Subramoney and Ana Henry, as well as René Bruno for his feedback on the manuscript.

Author information



Corresponding author

Correspondence to Andrijana Radivojevic.

Ethics declarations

Conflict of interest

A.R. is an employee of IntiGrowth LLC, B.C. of Pfizer Global Research, N.D. of Bayer AG, R.F. and H.L. of AstraZeneca, J.F.-K. of Cognigen Corporation (a SimulationsPlus company), M.M. of Amgen Inc., D.R. of Eli Lilly and Company, P.S. of VCA-Plus, J.S. of Merck, M.J.S. of Simcyp (a Certara company), N.S.T. of Certara, N.T. of Bristol-Myers Squibb, A.Z. of Janssen Pharmaceutical Companies of Johnson & Johnson, J.J.W. of Occams.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Radivojevic, A., Corrigan, B., Downie, N. et al. Data standards for model-informed drug development: an ISoP initiative. J Pharmacokinet Pharmacodyn 45, 659–661 (2018).

Download citation


  • Pharmacometric Analyses
  • Clinical Data Interchange Standards Consortium
  • Study Data Tabulation Model (SDTM)
  • Inform Dose Selection
  • Covers Input Data